The evolution of gene transfer, gene therapy, and the RAC: IOM recommendations to the NIH director

Howard J. Federoff, John E. Wagner

Research output: Contribution to journalEditorialpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)685-686
Number of pages2
JournalMolecular Therapy
Issue number4
StatePublished - Apr 2014

Bibliographical note

Funding Information:
Nearly 40 years ago, the National Institutes of Health (NIH) Recombinant Advisory Committee (RAC) was chartered to address public and ethical concerns surrounding the development of recombinant DNA (rDNA) molecules for transfer across organisms. As the use of rDNA evolved toward first-in-human clinical trials, the RAC reoriented its mission toward review of human subject risks. With the reconfigured scope, the RAC had authority to review all NIH-funded rDNA studies, including approval of clinical trials separate from the US Food and Drug Administration (FDA).

Cite this